Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and...

Area of Science:

• Cardiology
• Electrophysiology
• Clinical Trials

Background:

• Atrial fibrillation (AF) incidence is rapidly increasing worldwide.
• Current treatments for AF include anti-arrhythmic drug therapy and catheter ablation.
• The optimal treatment strategy for AF remains debated.

Purpose of the Study:

• To test the hypothesis that catheter ablation is superior to drug therapy for eliminating AF.
• To compare the efficacy and safety of catheter ablation versus state-of-the-art pharmacologic therapy in patients with AF.

Main Methods:

• The international, 140-center CABANA trial randomized 2200 patients with AF to either catheter ablation or drug therapy.
• Patients were followed for a median of 4 years with regular monitoring and subgroup imaging studies.
• Inclusion criteria focused on patients aged over 65 or younger with stroke risk factors, requiring treatment for AF and eligible for both interventions.

Main Results:

• The study was powered to detect a 30% relative reduction in a composite endpoint including mortality, stroke, bleeding, and cardiac arrest.
• Secondary endpoints assessed included mortality, cardiovascular hospitalizations, AF recurrence, quality of life, and cost-effectiveness.
• Projected to have 90% power with 1100 patients in each arm.

Conclusions:

• CABANA provides critical evidence to guide AF therapy decisions.
• Findings will help shape healthcare policy for managing the growing burden of AF.
• The trial's results are anticipated to influence clinical practice for years to come.